An Improved Cell Culture Process for Production of Omalizumab

  • Kaumil Bhavsar Associate Director- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Kasuhal Joshi Senior Director – IPR and R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Ghanshyam Patel Scientist II- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Parth Vaishnav Scientist I- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Om Narayan Senior Vice President- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Abhishek Sharma Senior Executive -IPR, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Hetal Katrodiya Assistant General Manager- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Vivek Dave Senior Scientist- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India
  • Chandramauli Rawal Chief Operating Officer (COO), Kashiv BioSciences, LLC, New Jersey, USA
Keywords: antibody, omalizumab, mammalian cells, acidic variants

Abstract

The demand for biopharmaceutical products such as monoclonal antibodies (MAbs), fusion proteins, viral vaccines, and hormones is rapidly increasing. Mammalian cell cultures with ease of process operations are adopted to get the desired product. The challenges of low productivity and impurities in the desired product can be eliminated by optimizing the process parameters. The present study focuses on the optimization of temperature with other parameters to achieve improved titer and reduced heterogeneity in Omalizumab. An anti-IgE antibody expressed in mammalian cell culture.  It is noticed that maintaining a specific temperature of 36.5° C ± 0.5 and pH 6.8± 0.1 during fed-batch cell culture provides improved quality (reduced galactosylation and reduced acidic variants) and quantity (improved titer) of the Omalizumab.

Keywords: antibody, omalizumab, mammalian cells, acidic variants

Downloads

Download data is not yet available.

Author Biographies

Kaumil Bhavsar, Associate Director- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Associate Director- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Kasuhal Joshi, Senior Director – IPR and R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Senior Director – IPR and R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Ghanshyam Patel, Scientist II- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Scientist II- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Parth Vaishnav, Scientist I- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Scientist I- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Om Narayan, Senior Vice President- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Senior Vice President- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Abhishek Sharma, Senior Executive -IPR, Kashiv BioSciences Private Limited, Ahmedabad, India

Senior Executive -IPR, Kashiv BioSciences Private Limited, Ahmedabad, India

Hetal Katrodiya, Assistant General Manager- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Assistant General Manager- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Vivek Dave, Senior Scientist- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Senior Scientist- R&D, Kashiv BioSciences Private Limited, Ahmedabad, India

Chandramauli Rawal, Chief Operating Officer (COO), Kashiv BioSciences, LLC, New Jersey, USA

Chief Operating Officer (COO), Kashiv BioSciences, LLC, New Jersey, USA

References

Sharker SM, Rahman A. A Review on the Current Methods of Chinese Hamster Ovary (CHO) Cells Cultivation for the Production of Therapeutic Protein. Curr Drug Discov Technol. 2021; 18(3):354-364. https://doi.org/10.2174/1570163817666200312102137 PMid:32164511

https://www.bioreactors.net/bioreactor-operational-requirements (accessed 4 July 2023)

Radhakrishnan D et al. Strategies to enhance productivity and modify product quality in therapeutic proteins. Curr. Opin. Chem. Eng. (2018). https://doi.org/10.1016/j.coche.2018.09.005

Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. (2001) Aug; 108(2):184-90. https://doi.org/10.1067/mai.2001.117880 PMid:11496232

Du Y, Walsh A, Ehrick R, Xu W, May K, Liu H. Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies. MAbs. (2012) Sep-Oct; 4(5):578-85. https://doi.org/10.4161/mabs.21328 PMid:22820257 PMCid:PMC3499298

McDonald AG, Hayes JM, Bezak T, Głuchowska SA, Cosgrave EF, Struwe WB, Stroop CJ, Kok H, van de Laar T, Rudd PM, Tipton KF, Davey GP. Galactosyltransferase 4 is a major control point for glycan branching in N-linked glycosylation. J Cell Sci. 2014; 127(Pt 23):5014-26. https://doi.org/10.1242/jcs.151878 PMid:25271059 PMCid:PMC4248093

Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. (2005) Nov-Dec; 21(6):1644-52. https://doi.org/10.1021/bp050228w PMid:16321047

Szabo M, Filep C, Nagy M, Sarkozy D, Szigeti M, Sperling E, Csanky E, Guttman A, N-glycosylation structure - function characterization of Omalizumab, an anti-asthma biotherapeutic product. J. Pharm. Biomed. Anal., 209 (2022), Article 114483, https://doi.org/10.1016/j.jpba.2021.114483 PMid:34864596

Published
2023-09-15
How to Cite
1.
Bhavsar K, Joshi K, Patel G, Vaishnav P, Narayan O, Sharma A, Katrodiya H, Dave V, Rawal C. An Improved Cell Culture Process for Production of Omalizumab. JDDT [Internet]. 15Sep.2023 [cited 8Sep.2024];13(9):15-9. Available from: https://jddtonline.info/index.php/jddt/article/view/6194